|
|||||
|
|
Inflammatory Markers in Schizophrenia: Comparing Antipsychotic Effects in Phase 1 of the Clinical Antipsychotic Trials of Intervention Effectiveness Study |
|
| Authors: | Jonathan M. Meyer Joseph P. McEvoy Donald C. Goff Henry A. Nasrallah John K. Hsiao T. Scott Stroup |
| Affiliation: | a Department of Psychiatry, University of California at San Diego, San Diego, California b VA San Diego Healthcare System, San Diego, California c Department of Psychiatry, Behavioral Sciences, Duke University, Clinical Research, John Umstead Hospital, Butner, North Carolina d Department of Biostatistics, Collaborative Studies Coordinating Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina e Department of Psychiatry, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina f Department of Psychiatry, Behavioral Sciences, Duke University Medical Center, Durham, North Carolina g Quintiles, Morrisville, North Carolina h Department of Psychiatry, Harvard University, Schizophrenia Program, Boston, Massachusetts i General Hospital, Freedom Trail Clinic—Lindemann, Mental Health Center, Boston, Massachusetts j Neuroscience, University of Cincinnati, Cincinnati, Ohio k Adult Psychopharmacology Program, Division of Services and Interventions Research, National Institute of Mental Health, Bethesda, Maryland l Department of Psychiatry, Columbia University, Psychiatric Institute, New York, New York |
| Abstract: | |
| Keywords: | Antipsychotic cardiovascular risk C-reactive protein E-selectin ICAM-1 inflammation schizophrenia VCAM-1 |
| 本文献已被 ScienceDirect 等数据库收录！ | |